[HTML] sciencedirect.com

[HTML][HTML] RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients with EGFR-Mutated Metastatic NSCLC

M Nishio, K Nishio, M Reck, EB Garon… - JTO Clinical and …, 2022 - Elsevier
Introduction Ramucirumab (RAM) plus erlotinib was found to have superior progression-free
survival (PFS) versus placebo plus erlotinib in untreated EGFR-mutated metastatic NSCLC …
被引用次数：1 相关文章

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC.

M Nishio, K Nishio, M Reck, EB Garon… - JTO Clinical and …, 2022 - europepmc.org
Methods Period 1 evaluated RAM (10 mg/kg) plus GEF (250 mg/d) in patients with untreated
EGFR-mutated metastatic NSCLC. Period 2 evaluated RAM plus osimertinib (80 mg/d) in …

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC

M Nishio, K Nishio, M Reck… - JTO clinical and …, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction Ramucirumab (RAM) plus erlotinib was found to have superior progression-free
survival (PFS) versus placebo plus erlotinib in untreated EGFR-mutated metastatic NSCLC …
[HTML] jtocrr.org

[HTML][HTML] RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC

M Nishio, K Nishio, M Reck, EB Garon… - JTO Clinical and …, 2022 - jtocrr.org
Introduction Ramucirumab (RAM) plus erlotinib was found to have superior progression-free
survival (PFS) versus placebo plus erlotinib in untreated EGFR-mutated metastatic NSCLC …
[HTML] nih.gov

[HTML][HTML] RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC

M Nishio, K Nishio, M Reck, EB Garon… - JTO Clinical and …, 2022 - ncbi.nlm.nih.gov
Methods Period 1 evaluated RAM (10 mg/kg) plus GEF (250 mg/d) in patients with untreated
EGFR-mutated metastatic NSCLC. Period 2 evaluated RAM plus osimertinib (80 mg/d) in …

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC.

M Nishio, K Nishio, M Reck, EB Garon… - JTO Clinical and …, 2022 - europepmc.org
Methods Period 1 evaluated RAM (10 mg/kg) plus GEF (250 mg/d) in patients with untreated
EGFR-mutated metastatic NSCLC. Period 2 evaluated RAM plus osimertinib (80 mg/d) in …